Related Experiment Video

Updated: Aug 17, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

ZD6474--clinical experience to date

J V Heymach1

  • 1Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA. John_Heymach@dfci.harvard.edu

British Journal of Cancer
|June 2, 2005
PubMed

Insights

ZD6474, a novel agent, targets tumor growth by inhibiting vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) pathways. Ongoing Phase II trials evaluate its efficacy in non-small-cell lung cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Tumor growth is driven by angiogenesis and cell proliferation.
  • Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor (EGF) are key signaling molecules.
  • Targeted therapies offer new approaches to cancer treatment.

Purpose of the Study:

  • To evaluate the safety and efficacy of ZD6474, a dual inhibitor of VEGF and EGF pathways.
  • To assess ZD6474 in monotherapy and combination regimens for non-small-cell lung cancer (NSCLC).
  • To explore optimal clinical trial designs for molecularly targeted agents.

Main Methods:

  • Phase I clinical evaluation of ZD6474 for safety and tolerability.
  • Phase II randomized trials in NSCLC patients comparing ZD6474 monotherapy vs. gefitinib.
  • Phase II trials evaluating ZD6474 in combination with chemotherapy (carboplatin/paclitaxel or docetaxel).

Main Results:

  • Phase I showed ZD6474 to be generally well tolerated with suitable pharmacokinetics for daily oral dosing.
  • Phase II trials are ongoing, assessing ZD6474 in various NSCLC patient populations and treatment settings.
  • Efficacy data from ongoing trials will determine ZD6474's role in NSCLC treatment.

Conclusions:

  • ZD6474 demonstrates a promising safety profile and targets critical tumor growth pathways.
  • Ongoing clinical trials will elucidate the therapeutic potential of ZD6474 in NSCLC.
  • The development of ZD6474 highlights the need for adaptive clinical trial designs for targeted cancer therapies.

More Related Videos

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation06:32

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation

Published on: July 14, 2023

Using Simulation Models to Train Clinicians in the Use of Point-of-Care Ultrasound05:04

Using Simulation Models to Train Clinicians in the Use of Point-of-Care Ultrasound

Published on: August 9, 2024

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...